Case report: Reproductive organ preservation and subsequent pregnancy for an infertility patient with lynch syndrome-associated synchronous endometrial cancer and colon cancer after treatment with a PD-1 checkpoint inhibitor
暂无分享,去创建一个
Cong Li | Fu-long Wang | Miao Wu | Rong-xin Zhang | Yu Gao | Diem T. Cao | Dan-dan Li | Yi-fan Liu | Gong Chen
[1] T. Gambichler,et al. Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma. , 2022, Melanoma research.
[2] G. Gullo,et al. Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review , 2022, International journal of molecular sciences.
[3] J. Haanen,et al. Immunotherapy for cancer treatment during pregnancy. , 2021, The Lancet. Oncology.
[4] G. Scambia,et al. Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification , 2021, International journal of molecular sciences.
[5] A. S. Laganà,et al. Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview , 2021, International journal of molecular sciences.
[6] Yuki Yamamoto,et al. Malignant melanoma treated with pembrolizumab during pregnancy: A case report and review of the literature , 2021, Molecular and clinical oncology.
[7] F. Garcia-Bournissen,et al. Pregnancy outcome after early exposure to nivolumab, a PD-1 checkpoint inhibitor for relapsed Hodgkin’s lymphoma , 2021, Clinical toxicology.
[8] A. Andrikopoulou,et al. Immune checkpoint inhibitor administration during pregnancy: a case series , 2021, ESMO open.
[9] N. Raghuraman,et al. Term Pregnancy After Complete Response of Placental Site Trophoblastic Tumor to Immunotherapy , 2021, Obstetrics and gynecology.
[10] N. Johnson,et al. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma , 2021, Cancer reports.
[11] J. Haiduk,et al. Pregnancy in a patient with metastatic uveal melanoma treated with nivolumab , 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[12] Qi Wang,et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. , 2021, Gynecologic oncology.
[13] O. Karaaslan,et al. Novelties of ultrasound imaging for endometrial cancer preoperative workup. , 2020, Minerva medica.
[14] G. Lippi,et al. Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer , 2020, Pathology & Oncology Research.
[15] G. Gullo,et al. Closed vs. Open Oocyte Vitrification Methods Are Equally Effective for Blastocyst Embryo Transfers: Prospective Study from a Sibling Oocyte Donation Program , 2020, Gynecologic and Obstetric Investigation.
[16] I. G. Glitza Oliva,et al. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. , 2020, Melanoma research.
[17] P. Therasse. Immune-Related Response Criteria , 2020, Definitions.
[18] S. Garzon,et al. Presence of Glandular Cells at the Preoperative Cervical Cytology and Local Recurrence in Endometrial Cancer , 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[19] V. Atkinson,et al. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. , 2019, Melanoma research.
[20] A. Enk,et al. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. , 2018, European journal of cancer.
[21] M. Burotto,et al. Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. , 2018, Seminars in oncology.
[22] C. Boland,et al. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes , 2018, CA: a cancer journal for clinicians.
[23] David Moher,et al. CARE guidelines for case reports: explanation and elaboration document. , 2017, Journal of clinical epidemiology.
[24] G. Gullo,et al. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial , 2017, Journal of Assisted Reproduction and Genetics.
[25] J. Degeorge,et al. An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors. , 2016, Birth defects research. Part B, Developmental and reproductive toxicology.
[26] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[27] A. Salama,et al. Oncotargets and Therapy Dovepress Clinical Applications of Pd-1-based Therapy: a Focus on Pembrolizumab (mk-3475) in the Management of Melanoma and Other Tumor Types , 2022 .
[28] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[29] B. Preston,et al. Case Series , 2010, Toxicologic pathology.
[30] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[31] Jan Willem van der Laan,et al. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. , 2009, Birth defects research. Part B, Developmental and reproductive toxicology.
[32] H T Lynch,et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.
[33] R. Broaddus,et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] K. Hongo,et al. A case report and review of the literature , 2006, Journal of Neuro-Oncology.